The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational study.
Santarsieri A, Mitchell E, Pham MH, Sanghvi R, Jablonski J, Lee-Six H, Sturgess K, Brice P, Menne TF, Osborne W, Creasey T, Ardeshna KM, Baxter J, Behan S, Bhuller K, Booth S, Chavda ND, Collins GP, Culligan DJ, Cwynarski K, Davies A, Downing A, Dutton D, Furtado M, Gallop-Evans E, Hodson A, Hopkins D, Hsu H, Iyengar S, Jones SG, Karanth M, Linton KM, Lomas OC, Martinez-Calle N, Mathur A, McKay P, Nagumantry SK, Phillips EH, Phillips N, Rudge JF, Shah NK, Stafford G, Sternberg A, Trickey R, Uttenthal BJ, Wetherall N, Zhang XY, McMillan AK, Coleman N, Stratton MR, Laurenti E, Borchmann P, Borchmann S, Campbell PJ, Rahbari R, Follows GA.
Santarsieri A, et al. Among authors: pham mh.
Lancet Oncol. 2024 Dec 11:S1470-2045(24)00598-9. doi: 10.1016/S1470-2045(24)00598-9. Online ahead of print.
Lancet Oncol. 2024.
PMID: 39674188
Free article.